A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
Study Details
Study Description
Brief Summary
The objective of this study is to describe the observed safety profile of Xospata® 40 mg tablet when administered in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study is being mandated by Ministry of Food and Drug Safety (MFDS) as a part of the Korea-Risk Management Plan (K-RMP) to assess safety in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea. This study collects data for 36 months according to the purpose of this study in routine clinical practice as an observational study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Xospata Patients who receive Xospata® 40 mg tablet in routine clinical practice according to the drug label approved at the time of marketing authorization. |
Drug: Gilteritinib Exposure
Oral
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of participants with Adverse Drug Reactions (ADRs) related to important identified and/or potential risks [Up to a maximum of 36 months (until 30 days after the last dose)]
An Adverse Drug Reaction refers to any unfavorable and unintended reaction occurring with a normal administration or use of the medicinal product that a causal relationship to the medicinal product cannot be ruled out. Number of ADRs related to important identified risks such as posterior reversible encephalopathy syndrome (PRES), QT prolongation, differentiation syndrome, and/or important potential risks such as pancreatitis, embryo-fetal lethality, suppressed fetal growth and teratogenicity, will be recorded.
- Number of participants with serious ADRs related to important identified and/or potential risks [Up to a maximum of 36 months (until 30 days after the last dose)]
An ADR refers to any unfavorable and unintended reaction occurring with a normal administration or use of the medicinal product that a causal relationship to the medicinal product cannot be ruled out. Number of ADRs related to important identified risks such as posterior reversible encephalopathy syndrome (PRES), QT prolongation, differentiation syndrome, and/or important potential risks such as pancreatitis, embryo-fetal lethality, suppressed fetal growth and teratogenicity, will be recorded. An ADR is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or prolongation of hospitalization, or other medically important event.
Secondary Outcome Measures
- Number of participants with ADRs related to identified risks and considered not important [Up to a maximum of 36 months (until 30 days after the last dose)]
An ADR refers to any unfavorable and unintended reaction occurring with a normal administration or use of the medicinal product that a causal relationship to the medicinal product cannot be ruled out. Number of ADRs related to identified risks but considered not important, such as other ADRs described by the Korean package insert, will be recorded. An ADR is considered "serious" if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or prolongation of hospitalization, or other medically important event.
- Number of participants with AEs [Up to a maximum of 36 months (until 30 days after the last dose)]
An AE is defined as any untoward medical occurrence in a subject administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE is considered "serious" if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or prolongation of hospitalization, or other medically important event. Causal relationship between the study drug is judged by medically qualified investigator either as certain, probable/likely, possible, unlikely, conditional/unclassified or unassessable/unclassifiable.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who receive Xospata® 40 mg tablet according to the drug label approved at the time of marketing authorization in routine clinical practice.
-
Patients who voluntarily signed the written informed consent form.
Exclusion Criteria:
-
Patients who meet the section 'Do not administer to the following patients' in the precautions for use given at the time of marketing authorization.
-
Patients who use the drug for an off-label purpose.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Site KR82006 | Goyang-si | Gyeonggi-do | Korea, Republic of | 10408 |
| 2 | Site KR82003 | Jeollanam-do | Hwasun-gun | Korea, Republic of | 58128 |
| 3 | Site KR82001 | Incheon | Korea, Republic of | 21565 | |
| 4 | Site KR82005 | Seoul | Korea, Republic of | 03722 | |
| 5 | Site KR82002 | Seoul | Korea, Republic of | 06351 |
Sponsors and Collaborators
- Astellas Pharma Korea, Inc.
Investigators
- Study Director: Astellas Pharma Korea, Inc., Astellas Pharma Korea, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2215-PV-001